Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378357 | 0.89 | FPR3 (0.51) | NAMPTFPR3FPR2 | |
| SCHEMBL24001121 | 0.87 | CNR1 (0.45) | NAMPTPOLBCNR1ALDH1A1 | |
| SCHEMBL589083 | 0.79 | FAAH (0.54) | CA1CA2BCHEACHE | |
| SCHEMBL15187489 | 0.77 | KMT2A (0.52) | NAMPTMEN1KMT2ANPC1KDM4E | |
| SCHEMBL11121639 | 0.76 | L3MBTL1 (0.36) | POLBCYP1A2CYP2D6CYP2C9NPC1 | |
| SCHEMBL8631416 | 0.76 | L3MBTL1 (0.36) | MEN1POLBKMT2ACYP1A2CYP2D6 | |
| SCHEMBL4368215 | 0.76 | ALOX15 (0.53) | MEN1POLBKMT2ACYP1A2CYP2D6 | |
| SCHEMBL365587 | 0.75 | RAB9A (0.50) | KMT2AKDM4EALDH1A1FPR3FPR2 | |
| SCHEMBL5413421 | 0.75 | FPR3 (0.33) | NPC1ALDH1A1FPR3FPR2 | |
| SCHEMBL4140655 | 0.74 | L3MBTL1 (0.39) | POLBCYP1A2CYP2D6CYP2C9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292604-B1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| EP-1292604-B1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7094769-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2006-06-08 | — | — | US | disclosed |
| US-6921753-B2 | Purine derivatives | PFIZER INC (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040229838-A1 | Purine derivatives | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| US-6753322-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-06-22 | — | — | US | disclosed |
| EP-1296996-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2004-05-26 | — | — | EP | disclosed |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-04-22 | — | — | US | disclosed |
| EP-1292604-A1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | Pfizer Limited (GB) | 2003-03-19 | — | — | EP | disclosed |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
| US-20020032168-A1 | Purine derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2001094368-A1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229838-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | CA12 4712/4885CA1 3146/4885CA2 2655/4885 |
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | CA12 3528/4885CA1 3399/4885CA2 2747/4885 |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | CA12 3588/4885CA1 3380/4885CA2 2728/4885 |
| US-20020032168-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | CA12 4712/4885CA1 3146/4885CA2 2655/4885 |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A1 | CA12 3790/4885CA1 3211/4885CA2 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.